Skip to content

Precision diagnosis and stratification treatment of myeloid sarcoma

Precision diagnosis and stratification treatment of myeloid sarcoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067379
Enrollment
Unknown
Registered
2023-01-05
Start date
2021-04-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloid Sarcoma (MS)

Interventions

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age >= 14 years old (pre-menopausal women with negative result of pregnancy test); 2. According to WHO criteria (2016), the pathological biopsy or puncture specimen is diagnosed with MS; 3. Expected survival time >= 3 months.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women, and women planning to conceive within one year; 2. With other solid malignancies (except resected cutaneous melanonma, in-situ carcinoma and thyroid papilloma); 3. Other unsuitable conditions for enrollment judged by clinicians (for instance, other diseases that effect treatment seriously).

Design outcomes

Primary

MeasureTime frame
fusion gene;gene mutations;bone marrow smear flow cytometry;

Secondary

MeasureTime frame
Imaging evaluation of target lesions of granulocytic sarcoma;

Countries

China

Contacts

Public ContactYu Wu

West China Hospital of Sichuan University

wu_yu@scu.edu.cn+86 189 8060 1973

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026